In women who have started estrogen replacement, suggests evaluating AED levels and adjusting AED doses as required. Triggers include: woman on estrogen replacement requiring AED management.
Installs into .claude/skills of the current project.
Are you the author of Ata Aed Estrogen Adjustment?
Add the live security badge to your README. It updates with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-ata-aed-estrogen-adjustment)
---
name: ata-aed-estrogen-adjustment
description: In women who have started estrogen replacement, suggests evaluating AED levels and adjusting AED doses as required. Triggers include: woman on estrogen replacement requiring AED management.
---
# Evaluate AED levels and adjust doses in women on estrogen replacement
## STEP 1 — Gather Information
Collect patient's current AED regimen (drug, dose, frequency), estrogen replacement details (type, dose, start date), baseline AED level if available, and assess for seizure control or adverse effects.
## STEP 2 — Rule In / Rule Out
Determine whether the prescribed AED is highly protein bound (>80%) (e.g., phenytoin, valproic acid, carbamazepine). If yes, proceed to level measurement; if no, rely on clinical assessment and routine follow‑up.
## STEP 3 — Classify or Stratify
Measure the AED total serum level and compare it to the laboratory‑specific therapeutic range; classify as subtherapeutic, therapeutic, or supratherapeutic.
## STEP 4 — Decide
If subtherapeutic, increase dose; if supratherapeutic, decrease dose; if therapeutic, maintain current dose; in all cases, recheck level after 1‑2 weeks or sooner if symptoms change.
## Clinical Guardrails / Mimics / Pitfalls
Do not adjust dose based solely on total level for highly protein bound AEDs without considering free fraction or clinical status; avoid dose changes in asymptomatic patients with stable seizure control; remember estrogen raises CBG, SHBG, and TBG, which can elevate total levels of highly bound drugs while free fraction remains unchanged; monitor for both seizure recurrence and signs of toxicity (e.g., nystagmus, ataxia, sedation).
## Concrete Clinical Example
A 32‑year‑old woman on transdermal estradiol 50 µg/day for hypopituitarism‑related central hypogonadism starts phenytoin 100 mg nightly for new‑onset seizures. After 2 weeks, her total phenytoin level is 24 µg/mL (therapeutic 10‑20 µg/mL) but she is seizure‑free and has no toxicity. Because estrogen increases protein binding, the free fraction is likely unchanged; the dose is maintained and level is rechecked in 4 weeks.
**Source:** Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118
